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AbstrAct
In recent years, several studies have presented evidence suggesting a potential 
role for metformin in anti-cancer therapy. Preclinical studies have demonstrated 
several anticancer molecular mechanisms of metformin including mTOR inhibition, 
cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated 
decreased cancer incidence and mortality in patients taking metformin. Several clinical 
trials, focused on evaluation of metformin as an anti-cancer agent are presently 
underway. Data published from a small number of completed trials has put forth 
intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited 
a significant decrease in Ki67 with metformin monotherapy. Another interesting 
observation was made in patients with breast cancer, wherein a trend towards 
improvement in cancer proliferation markers was noted in patients without insulin 
resistance. Data on survival outcomes with the use of metformin as an anti-cancer 
agent is awaited. This manuscript will critically review the role of metformin as a 
potential cancer treatment. 
IntroductIon
Metformin is one of the most widely prescribed oral 
anti-diabetic medications. It is the first line therapy for 
type 2 diabetes mellitus [1]. It has an anti-hyperglycemic 
effect which is mediated by inhibiting gluconeogenesis, 
decreasing glucose absorption from the small intestine, 
increasing glucose uptake in cells, and decreasing plasma 
free fatty acid concentration [2]. Metformin also increases 
insulin induced translocation of glucose transporters 
to the cellular plasma membrane, thus reducing insulin 
resistance [3]. Use of metformin has been found to be 
generally safe, with mild gastrointestinal symptoms being 
the most common adverse effects [4].
There is substantial preclinical evidence suggesting 
that metformin has anti-cancer properties. In-vitro and in-
vivo analysis of metformin has exhibited anti-proliferative 
activity by inhibiting intracellular pathways. It has also 
been observed that metformin activates the T cell mediated 
immune response against cancer cells.
Numerous retrospective studies have reported that 
metformin is associated with a reduced risk of developing 
cancer. Meta-analysis of data obtained from cohort and 
observational studies has revealed that metformin use was 
associated with a decrease in both cancer related and all-
cause mortality. 
Here we summarize the available evidence from 
clinical trials of metformin as part of cancer therapy. We 
review the landscape of current investigation and suggest 
directions for future investigation. 
PreclInIcAl dAtA
Metformin has been extensively studied in 
preclinical models, which has revealed numerous 
molecular pathways that it modulates, either directly 
                                                         Review
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table 1: Proof of concept for anti-tumor activity of metformin
cancer type Phase Primary outcome/conclusion dosing regimen combination
enrollment 
no. status results
clinical trial 
identifier/ Reference
Bladder Phase II
Changes in Ki67 
when comparing 
TURBT and 
cystectomy tissue.
Metformin 850mg and 20 
mg of Simvastatin daily 
from the time of enrollment 
in study untill the day before 
surgery (an approximate 
duration of 12 weeks)
metformin, 
simvastatin 44
Not yet 
recruiting NA NCT02360618
Breast Phase 0
Tumor growth 
assessed by 
changes in ln Ki67
Metformin + atorvastatin 
PO
metformin, 
atorvastatin 40 Recruiting NA NCT01980823
Breast Phase II
Effects 
of metformin on 
AMPK/mTOR 
pathway
Metformin 1500mg/day, 
500mg (AM) and 1000mg 
(PM) for at least 2 weeks 
prior to surgery
metformin 
monotherapy 35 Published
- Non-significant difference in decrease of 
ln (Ki67) for both invasive and DCIS breast 
cancers (p= 0.98) or invasive breast cancer 
alone (p = 0.43). 
- No significant variation noted in changes of 
ln (Ki67) when metformin arm compared to 
control arm (p = .47). 
NCT00930579 
[41]
Breast Phase II
Effects 
of metformin in 
phosphorylation of 
S6K, 4E-BP-1 and 
AMPK
Extended release 
metformin 1500mg QD for 
14-21 days
metformin 
monotherapy 41 Completed NA NCT01266486
Breast Phase II RCT
Primary endpoint 
is change in 
Ki67. This study 
estimates apoptosis 
by TUNEL by 
comparing core 
and corresponding 
surgical biopsies.
Metformin 850mg QD for 
3 days followed by 850mg 
BID days 4-28
metformin 
monotherapy 200 Published
TUNEL levels elevated at surgery as 
compared to baseline biopsy (P<0.0001), 
no major difference between metformin 
arm and placebo arm; Ki67 labelling index 
and TUNEL levels at baseline & surgery in 
direct correlation; TUNEL levels higher with 
metformin than placebo in women without 
insulin resistance (metformin: +4%, IQR: 
2–14, placebo: +2%, IQR: 0–7), while the 
inverse observed in those who had insulin 
resistance (metformin: +2%, IQR: 0–6, 
placebo +5%, IQR: 0–15).
EudraCT 2008-
004912-10, Trial 
number S425/408 
[42]
Breast Phase II, single arm
Effect of metformin 
on tumor growth 
rate over 2 to 3 
weeks
Metformin 500 mg PO TID 
for 2-3 weeks before surgery
metformin 
monotherapy 39 Completed
HOMA levels significantly reduced; insulin, 
leptin and CRP had non-significant reductions; 
TUNEL staining increased from 0.56 to 1.05, 
p= 0.004; Ki67 staining decreased from 36.5 
to 33.5%, p= 0.016. 
NCT00897884 [37]
Breast Phase II 
RCT
Changes in Ki-67 Metformin 850-mg QD PO 
days 1- 3 for allowing time 
to adjust to GI symptoms; 
two 850mg tablets after 
dinner on days 4 - 28.
metformin 
monotherapy
200 Completed No statistically significant changes in Ki67 
with metformin, noting a mean proportional 
increase of 4.0% (95% CI: −5.6% to 14.4%) 
in 4 weeks;
Women with HOMA ≤ 2.8: non-significant 
increase of Ki67 by 11.1% (95% CI: −0.6% 
to 24.2%); women with HOMA ˃ 2.8: non-
significant mean proportional decrease in 
Ki67 by 10.5% (95% CI: −26.1% to 8.4%).
ISRCTN16493703 
[40]
Breast NA, RCT To determine 
the anti-cancer 
mechanism of 
metformin in 
breast cancer
Metformin 500mg QD for 1 
week followed by 1000mg 
BID until the day of surgery
metformin 
monotherapy
47 Published Metformin therapy showed no effect on tumor 
size.
With using Allred scoring (0-8)-
- Mean change in  pAMPK score:
Metformin- 5.18 to 6.45
Control arm- 5.64 to 6.00
- Change in pAKT staining score:
Metformin- 5.91 to 5.00
Control arm- 4.91 to 5.18
- Mean change in Ki67 staining:
Metformin- decrease by 3.4%
Control arm- stable
- Caspase-3 staining:
Metformin- reduced by 0.29%
Control arm- no significant change 
[39]
Breast, lung, 
liver, kidney, 
lymphoma
Phase I Effect of 
metformin 
plus sirolimus 
compared 
to sirolimus 
monotherapy on 
p70S6K
Sirolimus 3mg daily alone 
for the first 7 days. From 
day 8-21, metformin 
500mg QD. If tolerated, 
dose increased to 1000 mg 
QD on day 15. Patients 
developing grade 2 toxicity 
due to metformin to be 
maintained on 500mg QD 
for rest of study, while 
those with >grade 2 toxicity 
will be taken off study. Day 
22 onwards, all will be on 
combination of sirolimus + 
metformin
metformin, 
sirolimus
64 Recruiting NA NCT02145559
Endometrial Phase 0 Changes in Ki-67 Metformin 850mg PO QD metformin 
monotherapy
16 Completed 65% patients showed a fall in Ki-67 staining 
with metformin; those who showed response 
to metformin had higher pre-treatment Ki67 
levels; pAMPK, pS6, pAKT, p-4E-BP-1 and 
ER expression were reduced; PR unaffected; 
tumor proliferation decreased by 11.75% with 
metformin. 
NCT01911247 [43] 
Endometrial Phase II Changes in pS6 Metformin 500mg PO TID 
from enrollment in study 
till surgical staging. If side 
effects persist, dose will be 
reduced to 500mg PO BID.
metformin 
monotherapy
80 Not yet 
recruiting
NA NCT02042495
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or through other downstream targets, contributing to 
reduction in growth and proliferation of tumor cells. The 
inhibition of mTOR (mammalian target of rapamycin) in 
tumor cells is one of the potential key mechanisms that 
facilitates the anti-cancer activity of metformin. Use 
of metformin in MCF-7 breast cancer cells exhibited 
reduction in phosphorylation of S6 kinase, ribosomal 
protein S6 and eIF4E binding protein, along with 
inhibition of mTOR and reduced translation initiation 
due to AMPK activation [5]. Animal models of pancreatic 
cancer fed with metformin showed inhibition of insulin 
like growth factor-1 (IGF-1) and mTOR, along with an 
increase in phosphorylated AMPK and tuberous sclerosis 
complex (TSC1, TSC2) [6]. The AMPK mediated 
phosphorylation of TSC2 has been observed to increase 
the activity of TSC2, leading to inactivation of mTOR [7, 
8]. AMPK has been described to directly inhibit mTORC1 
through phosphorylation of mTOR binding raptor as well 
[9]. Comparing the effects of metformin with rapamycin, a 
direct mTOR inhibitor, metformin decreases the activation 
of AKT in addition to AMPK dependent mTOR inhibition. 
Thus, metformin renders a better anti-tumor response 
than rapamycin in breast cancer cells [10]. Metformin 
has been found to decrease HER2 expression in human 
breast cancer cells by directly inhibiting p70S6K1, which 
is a downstream effector of mTOR [11]. In a study using 
nude mice with acute myeloid leukemia (AML), the use of 
metformin was correlated with a decrease in proliferation 
of AML cells. This action was characterized by the 
activation of LKB1/AMPK/TSC pathway, which led to 
mTOR inhibition and consequently suppression of mRNA 
translation [12]. In tobacco carcinogen induced lung 
cancer mice, the inhibition of insulin like growth factor 
1 receptor/insulin receptor (IGF- 1R/IR) by metformin 
decreased the downstream signaling through Akt pathway. 
This reduced the activation of mTOR in lung tissue which 
corresponded to a 72% reduction in tumor burden [13]. 
Metformin can inhibit the activation of mTOR 
independent of AMPK pathway as well. Metformin has 
been shown to escalate the expression of REDD1 by 
Endometrial Phase II RCT
Changes in Ki67, 
phosphorylated 
histone H3, 
estrogen receptor, 
progesterone 
receptor, and 
telomerase.
NA metformin monotherapy 40 Recruiting NA
NCT01877564
Endometrial NA
Effect of metformin 
on tumor 
proliferation
Metformin 500mg TID from 
diagnostic biopsy to surgery 
(average of 36.6 days)
metformin 
monotherapy 11 Published
Metformin use decreased IGF-1, mean plasma 
insulin, IGFBP-7, Ki67 (9.7%, p= 0.02) and 
pS6 (31%, p= 0.03) staining; Ki67 and pS6 in 
control group similar in baseline biopsy and 
surgical specimens. 
[44]
Endometrial NA Increase in s6K
Metformin 850mg QD for 
at least 7 days and up to 30 
days before surgery
metformin 
monotherapy 30
Active, but 
not recruiting NA
NCT01205672
Endometrial NA
Effect of anti-
diabetic dose of 
metformin on 
tumor proliferation
Metformin 1500 - 2250mg/
day for 4-6 weeks before 
surgery
metformin 
monotherapy 31 Published
Ki-67 mean proportional decrease= 44.2%; 
topoisomerase IIα mean proportional 
decrease= 36.4%; PRP S6 and ERK1/2 levels 
showed significant reduction while pAMPK 
and p27 had significant elevation. 
[45]
Head and Neck 
squamous cell Phase 0
Changes in 
TOMM20 and 
MCT4 in tumor 
tissue
NA metformin monotherapy 40 Recruiting NA
NCT02083692
Lung Phase II
Effect of metformin 
on plasma IL-6 
levels
Treatment with either 
cisplatin 75mg/m2 + 
pemetrexed 500mg/m2 on 
day1 for 4 cycles or targeted 
therapy with gefitinib 
250mg/day until disease 
progression. If plasma IL-6 
>2.0 pg/mL after 2 cycles 
of chemotherapy/targeted 
therapy, metformin 500mg 
PO QD will be given on day 
1 of cycle 3. If tolerated, 
metformin will be titrated 
to 500mg BID in next week 
(Cycle 3 day8) and 500mg 
TID in the 3rd week (Cycle 
3 day15); those receiving 
chemo will be given 
metformin for 12 weeks and 
those on targeted therapy 
will receive it till disease 
progression.
metformin, 
cisplatin, 
pemetrexed, 
gefitinib
48 Recruiting NA
NCT01997775
Prostate Phase II 
RCT
Changes in Ki67 
staining using 
IHC
Extended release 
metformin PO QD for 
4-12 weeks
metformin 
monotherapy
21 Active 
but not 
recruiting
NA NCT01433913
Prostate NA Assess safety, 
tolerability and 
change in Ki67 and 
AMPK pathway 
associated markers 
with the use of 
neoadjuvant 
metformin
Metformin 500mg TID Metformin 
monotherapy
24 Published Metformin decreased Ki67 index by 29.5% 
per patient and 28.6 % per tumor; P-4EBP1 
staining showed reduction and P-AMPK 
recorded no change; 3 cases developed grade 
3 toxicity. 
[48]
Abbreviations: PFS, progression free survival; RCT, Randomized control trial; TUNEL, Terminal deoxynucleotidyl transferase 
dUTP nick end labeling; P-AMPK, phosphorylated AMPK; HOMA, Homeostasis model assessment; IGF-1, insulin like 
growth factor-1; IQR, Interquartile ratio; PO, taken by mouth; QD, once a day; BID, two times a day; TID, three times a day
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a p53 mediated inhibition of mTOR in prostate cancer 
cells [14]. Another study described that metformin can 
prevent mTOR activation through Ras-related GTPase 
(RagGTPases), independent of AMPK, as well as TSC1/2 
[15].
Tumors are known to exhibit the Warburg effect, 
where tumor cells generate ATP from glycolysis instead 
of oxidative phosphorylation secondary to low nutrient 
supply and hypoxia [16]. Metformin blunts the Warburg 
effect and consequently downregulates the growth of 
cancer stem cells [17]. In-vivo studies on hepatocellular 
carcinoma xenografts have shown that metformin 
improves cellular oxygenation ability and decreases 
mitochondrial oxygen consumption, thus suppressing 
hypoxia-induced HIF-1α accumulation. These effects form 
the basis of anti-cancer activity of metformin, particularly 
against hepatocellular carcinoma [18]. 
In addition to the above, various other mechanisms 
of metformin for cell growth inhibition have been 
identified in pre-clinical models. Metformin therapy in 
paired isogenic colon cancer cell lines (HCT116 p53 [+/+] 
and HCT116 p53 [-/-]) showed an increase in apoptosis 
of p53 deficient cells [19]. In-vitro and in-vivo analysis 
of metformin therapy showed that it can inhibit growth 
of ovarian stem cells [20], glioma initiating cells [21], 
breast cancer cells [22], endometrial cancer cells [23] 
and non-small cell lung cancer cells [24]. It has also 
exhibited synergistic action with VEGF inhibitors to 
inhibit proliferation of BRAF mutant melanoma cells [25]. 
Additionally, it has been noted that metformin increases 
radiosensitivity of cancer cells [22, 24]. 
Recent experiments on animal models have also 
suggested that metformin has immune modulatory 
properties. Metformin inhibits immune exhaustion 
of CD8+ tumor induced lymphocytes (TIL), thereby 
enhancing T cell mediated immune response to tumor 
tissue. It decreases apoptosis of CD8+ tumor infiltrating 
lymphocytes (TILs), and also shifts the phenotype of 
CD8+ TILs expressing exhaustion markers (especially 
PD1 negative Tim3 positive) from central memory T cells 
(TCM, inactive against tumor cells) to effector memory 
T cells (TEM, active against tumor cells). The increase 
in TEM cell population has been found to correlate with 
regression of tumor cells [26]. In a study evaluating an 
experimental cancer vaccine, administration of metformin 
after vaccination in animal models showed an increase 
in CD8+ memory T cells which conferred protective 
immunity upon subsequent tumor challenge [27]. Figure 
1 summarizes the effects of metformin on various cellular 
pathways. 
Figure 1: Possible mechanisms of anti-cancer activity of metformin. The inhibition of mTORC1 is mediated by reducing the 
downstream effects of IGF-1 and insulin hormone receptor binding, increased TSC2 phosphorylation by AMPK, Rag GTPase mediated 
inhibition and phosphorylation of mTOR binding raptor by AMPK. This leads to inhibition of mRNA translation, ribosomal biogenesis 
and cell growth. Metformin also potentiates the immune system by reducing immune exhaustion of CD 8+ tumor infiltrating lymphocytes 
through phenotypic switching to memory cells, thus enhancing the immune response to cancer cells. Abbreviations: AMP, Adenosine 
monophosphate; AMPK, AMP activated protein kinase; GTPase, Ras-related GTPase; mTORC1, Mammalian receptor of rapamycin; 
TSC2, Tuberous sclerosis complex protein 2; PI3K, Phosphoinositide 3 kinase; Akt, Protein kinase B; IL-2, Interleukin-2; TNFα, Tumor 
necrosis factor -α; IFNγ, Interferon γ
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table 2: Anti-tumor activity of metformin in locally advanced and hematologic cancers
cancer type Phase Primary outcome/conclusion dosing regimen combination
enrollment 
no. status results
clinical trial 
identifier/ 
reference
AML Phase I MTD of metformin plus cytarabine
Metformin PO BID on days 1-15 and cytarabine IV 
over 3 hours BID on days 4-10.
metformin, 
cytarabine 28 Recruiting NA NCT01849276
Breast Phase II RCT
pCR rate 
(evaluated in 5 
months)
Docetaxel 75mg/m2 IV, epirubicin 75mg/m2 IV and 
cyclophosphamide 500mg/m2 IV day 1 of each 21 
day cycle; 6 cycles;  metformin 500mg TID PO 
(500mg daily in 1st cycle)
metformin, 
docetaxel, 
epirubicin, 
cyclophosphamide
200 Recruiting NA NCT01929811
Breast Phase II RCT
Clinical response 
rate
Letrozole 2.5mg PO daily, metformin 500mg BID 
PO daily x 1week; metformin 1000mg (am) & 500 
mg (pm) PO daily x 1week; metformin 1000mg BID 
PO daily x 22 weeks
metformin, 
letrozole 208 Recruiting NA NCT01589367
Breast Phase II RCT
To evaluate if using 
new chemotherapy 
drugs with standard 
neoadjuvant 
chemotherapy 
agents increases 
pCR.
AMG 479 (Ganitumab) 12 mg/kg IV every 2 weeks 
during 12 week cycle + metformin 850 mg PO every 
week during 12 weekly cycles post-randomization
metformin, 
ganitumab 800 Recruiting NA NCT01042379
Breast Phase III RCT
Invasive disease-
free survival
Metformin HCl PO BID (QD for first 4 weeks), for 
up to 5 years.
metformin 
monotherapy 3649
Active but not 
recruiting NA NCT01101438
Breast Phase III RCT
Evaluating atypia 
after 12 and 
24 months of 
metformin
Metformin HCl 850 mg PO BID for 24 months 
on arm 1, including 4 weeks escalation dosing 
of 850 mg PO QD. Patients initially randomized 
to the placebo arm (Arm 2) may crossover to the 
metformin arm (Arm 1) for months 13-24.
metformin 
monotherapy 400
Not yet 
recruiting NA NCT01905046
Chronic 
Lymphocytic 
Leukemia
Phase II
Time to treatment 
failure (assessed 
every 3 months)
Initial dose of metformin will be 500 mg PO QD for 
1 week, escalated to 500 mg BID after 1 week, and 
finally to 1000 mg BID in week 3 if tolerated.
metformin 
monotherapy 53 Recruiting NA NCT01750567
Colorectal Phase II
Disease Control 
Rate (assessed up 
to 1 year)
FOLFOX6+Metformin or FOFIRI + Metformin
metformin, 
FOLFOX6, 
FOFIRI
48 Recruiting NA NCT01926769
Endometrial Phase II CBR
Metformin 500 mg PO QD for days 1-4 of cycle 0 
and then BID after that. Metformin to be taken for 
7 - 10 days in cycle 0 before cycle 1 begins; letrozole 
2.5 mg PO QD in a 28 day cycle; everolimus 10 mg 
PO QD in a 28 day cycle.
metformin, 
letrozole, 
everolimus
64 Recruiting NA NCT01797523
Endometrial Phase II RCT
Pathological 
response rate 
(evaluated at 12 
weeks)
Metformin 500 mg PO third daily and megestrol 
acetate 150 mg PO QD for 3 months
metformin, 
megestrol acetate 150 Recruiting NA NCT01968317
Endometrial Phase II, 
III RCT
PFS (Phase II) 
(assessed up to 5 
years)
Day 1- paclitaxel IV over 3 hours and carboplatin 
IV; metformin PO BID on days 1-21 (QD in 
cycle 1). Treatment repeats every 21 days for 6 
cycles. Patients then receive maintenance therapy- 
metformin PO BID on days 1-21. Course repeated 
every 21 days.
metformin, 
paclitaxel, 
carboplatin
540 Recruiting NA NCT02065687
Glioblastoma 
Multiforme
Phase I MTD and PFS 
assessed at 6 
months
Temozolomide 150 mg/m2 PO on alternate weeks 
days 1-7, 15-21 of a 28 day cycle; metformin 1000 
mg PO BID for 28 day cycle.
metformin, 
temozolomide
144 Recruiting NA NCT01430351
Lung Phase II PFS (assessed for 
up to 52 weeks)
Metformin 1000 mg PO BID added to standard of 
care platinum based chemotherapy
metformin, 
platinum based 
chemotherapy
60 Recruiting NA NCT02019979
Lung Phase II 
RCT
PFS assessed at 
1 year
Gefitinib + metformin; metformin starting at 500 
mg TID PO. After 1 week, increase dose to 1000 
mg as the 1st dose of the day and 500 mg as the 
2nd dose. After another week, increase to 1000 mg 
TID. Metformin treatment will be initiated 1 week 
before TKI therapy if possible.
metformin, 
gefitinib
168 Recruiting NA NCT01864681
Ovary Phase I Assess safety and 
tolerability of the 
treatment
Escalating doses of metformin will be added to 
carboplatin IV / paclitaxel IV chemotherapy for 
up to 6 cycles.
metformin, 
carboplatin, 
paclitaxel
20 Not yet 
recruiting
NA NCT02312661
Ovarian, 
Fallopian 
Tube or 
Primary 
Peritoneal
Phase I Success rates of 
the combination 
chemotherapy
Day 1- paclitaxel IV over 3 hours, carboplatin 
IV, metformin HCl BID on days 1-21; treatment 
repeated every 21 days for 6 cycles
metformin, 
paclitaxel, 
carboplatin
18 Not yet 
recruiting
NA NCT02050009
Pancreas Phase II PFS at 12 
months
Everolimus + octreotide LAR + metformin metformin, 
everolimus, 
octreotide LAR
43 Recruiting NA NCT02294006
Pancreas Phase II 
RCT
RFS after 
surgery (assessed 
every 2 months 
during treatment 
and every 3 
months after 
completion, till 
24 months)
Metformin 500 mg BID initially, if tolerated, 
dose to be increased to 1000 mg BID in the 2nd 
week; gemcitabine 1000 mg/m2 (IV, 30 minutes) 
on days 1, 8, and 15 for 3 weeks, followed by 1 
week without treatment, and also receive placebo 
(Arm I)/ metformin (Arm II) on days 1-28. Course 
repeated every 4 weeks for up to 6 cycles.
metformin, 
gemcitabine
300 Recruiting NA NCT02005419
Prostate Phase I DLT assessed at 
28 days 
Enzalutamide PO QD and metformin HCl PO BID. 
Courses repeat every 28 days
metformin, 
enzalutamide
24 Not yet 
recruiting
NA NCT02339168
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ePIdemIology
There are numerous epidemiological studies that 
have put forth evidence suggesting utility of metformin as 
an anti-cancer agent.
Several observational and cohort studies have been 
conducted to assess the influence of metformin on cancer. 
Survival analysis in a cohort study on diabetic patients 
comparing metformin users (n = 4,085) to non-users (n 
= 4,085) reported a reduced risk of cancer (hazard ratio, 
HR = 0.63; 7.3% diagnosed with cancer in metformin 
users versus 11.6% in non-users) [28]. Meta-analysis 
performed on 37 studies, with a total of 1,535,636 patients 
comparing metformin users and non-users reported overall 
cancer incidence summary relative risk (SRR) as 0.73. 
The results also noted a reduction of cancer incidence for 
liver (78%), breast (6%), pancreatic (46%) and colorectal 
cancer (23%). However, no significant correlation could 
be derived between the use of metformin and incidence 
of prostate cancer [29]. Meta-analysis of 6 case control 
studies comparing 39,787 participants that were on 
metformin to 177,752 participants that were not, exhibited 
a lower risk of developing lung cancer in the metformin 
group (odds ratio, OR = 0.55; p < 0.001) [30]. Likewise, 
another meta-analysis showed a reduction in incidence 
of prostate cancer (RR = 0.88; p = 0.03) in patients who 
were on metformin treatment [31]. Meta-analysis of 35 
observational studies reported a considerable correlation 
with using metformin to reduce the risk of developing all-
cancer (OR = 0.73), liver cancer (OR = 0.34), colorectal 
cancer (OR = 0.83), pancreatic cancer (OR = 0.56), gastric 
cancer (OR = 0.83), and esophageal cancer (OR = 0.90) 
[32]. A recent meta-analysis of 265 studies showed the 
use of metformin or thiazolidinediones was associated 
with a lower incidence of cancer (RR = 0.86 and 0.93 
respectively). But interestingly, insulin, sulfonylureas, 
and alpha glucosidase inhibitor use was associated with 
an increased incidence of cancer (RR = 1.21, 1.20, 1.10 
respectively) [33].
Meta-analysis of retrospective studies has provided 
substantial evidence associating the use of metformin with 
a decrease in cancer related mortality. A cohort study, 
investigating mortality due to cancer in type 2 diabetes 
patients, showed a decrease in cancer related mortality risk 
(HR = 0.56) with the use of metformin [34]. Data from 
meta-analysis of 6 observational studies noted a significant 
correlation between using metformin and risk of cancer 
related mortality (OR = 0.65) [32]. Retrospective analysis 
of data from over 350 primary care practices in the United 
Kingdom found a decrease in cancer related mortality 
(HR = 0.85) in diabetic patients who were on metformin 
monotherapy when compared with those on other drugs 
for diabetes [35]. Another meta-analysis showed that 
the use of metformin in diabetic patients diagnosed with 
cancer was associated with a decrease in risk of all-
cause mortality in cancers of breast (pooled relative risk, 
RR = 0.70; p = 0.003), ovary (RR = 0.44; p < 0.001), 
endometrium (RR = 0.49; p = 0.001) and colorectal cancer 
(RR = 0.70; p < 0.001) [36]. 
In light of the available preclinical and retrospective 
data suggesting anti-cancer properties of metformin, 
clinical trials are necessary to further investigate its role 
in cancer therapy. 
methods
Information about the study drug was obtained from 
clinicaltrials.gov (a service of United States National 
Institutes of Health), using the search query “metformin” 
and “cancer”. Of the 223 results obtained from the search 
engine, relevant drug trials were selected. The published 
clinical trials were obtained from PubMed using the 
same search query and choosing the “clinical trial” 
filter. The publications that focused on use of metformin 
Solid tumors Phase I To evaluate DLT 
when metformin 
is added to a 
chemotherapy 
regimen that is 
well tolerated.
Stage 1- patients randomized to 2 arms- concurrent 
arm (metformin + chemo) and delayed arm (chemo 
alone). Stage 2- patients in delayed arm crossed 
over to concurrent arm; metformin dose- 500mg 
BID + chemotherapy
metformin, 
chemotherapy
100 Completed Metformin plus 
chemotherapy had 
a lower rate of 
DLTs (6.1%) as 
compared to those 
who received only 
chemotherapy 
(7.8%); Patients 
showing DLT with 
metformin included 
the ones already 
known to have 
adverse effects 
with chemotherapy; 
Post-treatment with 
metformin, AMPK 
phosphorylation 
increased by 4-6 
folds, 46% showed 
stable disease 
and 28% of the 
patients who had 
quantifiable tumor 
markers showed 
favorable changes. 
NCT01442870 
[49]
Uterus Phase II 
RCT
pCR (assessed 
at 6 months)
Metformin 500mg BID PO  + levonorgestrel 52mg 
IUD for 6 months
metformin, 
levonorgestrel
165 Recruiting NA NCT01686126
Abbreviations: RFS, recurrence free survival; PFS, Progression free survival; DLT, dose limiting toxicity; MTD, Maximum 
tolerable dose; pCR, Pathological complete response; RCT, Randomized control trial; CBR, Clinical benefit rate; IHC, 
immunohistochemistry; HOMA, Homeostasis model assessment; CI, Confidence interval; PO, taken by mouth; QD, once a 
day; BID, two times a day; TID, three times a day; IUD, Intra-uterine device
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for treatment of cancer in human subjects through a 
prospective clinical trial were identified and selected. 
The results of completed clinical trials were obtained 
from PubMed and online abstract library for professional 
societies such as the American Association of Cancer 
Research (AACR) and American Society of Clinical 
Oncology (ASCO). The AACR and ASCO online libraries 
were explored using the NCT number associated with the 
clinical trial. The authors, enrollment number, primary & 
secondary outcomes and primary location of conducting 
the research mentioned in abstracts collected from ASCO 
and AACR database were matched with the information 
obtained from clinicaltrials.gov to avoid any discrepancies 
in associating the abstracts to the appropriate trial. 
clInIcAl trIAls
Presently, there are 55 ongoing clinical trials 
in various stages that are evaluating metformin as a 
monotherapy (11 trials, 20% of all ongoing trials using 
metformin as an anti-cancer agent) or in combination 
with cytotoxic chemotherapy (38 trials, 69%) and/or 
radiotherapy (6 trials, 11%) for the treatment of cancer 
(Tables 1-4). These trials primarily focus on establishing 
the effects of metformin on markers of cellular 
proliferation, pathological response rate, progression free 
survival, and recurrence free survival. Also, certain trials 
are directed towards determining the maximum tolerable 
dose of metformin in specific tumors.
A considerable amount of focus has been laid on 
investigating metformin as a potential anti-cancer agent for 
cases of breast cancer. Eleven trials (20% of all ongoing 
trials using metformin as an anti-cancer agent; Tables 1-3) 
are focused on evaluating metformin as a treatment for 
breast cancer. Of these, two trials are using metformin 
as monotherapy. There are 9 trials using metformin in 
combination with other anti-cancer agents. These include 
capecitabine, cyclophosphamide, docetaxel, doxorubicin, 
erlotinib, epirubicin, exemestane, ganitumab, letrozole, 
sirolimus and temsirolimus. One trial is exploring the use 
of metformin plus atorvastatin combination as a possible 
treatment for breast cancer. Two trials using metformin 
combination therapy are also evaluating pathological 
complete response as a primary endpoint. Apart from 
the ongoing trials, data obtained from 5 completed trials 
(all using metformin monotherapy in a pre-surgical 
window of opportunity trial design) has facilitated a better 
understanding regarding the effects of metformin in breast 
cancer. In addition to survival outcomes, several surrogate 
markers are also being employed to study the effects of 
metformin on breast cancer cell population. These include 
Ki67, S6K, 4E-BP-1, AMPK and effects on AMPK/mTOR 
pathway. 
A phase 2 single arm window of opportunity trial of 
39 breast cancer cases [37] showed significant reduction 
in Ki67 (36.5 to 33.5 %, p = 0.016) and an increase in 
TUNEL staining (0.56 to 1.05, p = 0.004) along with 
significant fall in HOMA (homeostatic model assessment, 
used for determining the status of insulin resistance) [38]. 
A recently published randomized control trial (RCT) 
also reported a decrease in Ki67 staining (mean = 3.4%, 
p = 0.027). Additionally, it noted an increase in mean 
AMPK score, fall in pAKT score and reduced caspase-3 
staining in patient samples with the use of metformin 
when compared to placebo [39]. However, other trials 
have had conflicting outcomes. A phase II RCT with 
200 participants recorded no significant changes in 
Ki67 on comparing metformin and placebo arms. But, 
interestingly, the cases with HOMA ≤ 2.8 showed a non-
significant increase of Ki67 by 11.1% (95% Confidence 
interval (CI): -0.6% to 24.2%) and those with HOMA ˃ 
2.8 (implying a higher probability of insulin resistance) 
showed a non-significant mean proportional decrease in 
Ki67 by 10.5% (95% CI: -26.1% to 8.4%) [40]. Another 
phase II trial (non-randomized) examined effects of 
metformin in overweight/obese patients with stage 
0-III breast cancer. Though noting a correlation of Ki67 
with tumor growth, the calculated ln (Ki67) showed no 
significant changes when comparing metformin to placebo 
[41]. A different study with 200 participants randomized 
to metformin or placebo did not document any major 
difference in Ki67 and TUNEL levels (used for assessing 
cellular apoptosis) between the two arms. The study did 
note that TUNEL levels were higher in women without 
insulin resistance (metformin: +4%, interquartile range, 
IQR: 2-14, placebo: +2%, IQR: 0-7) as compared to those 
who had insulin resistance (metformin +2%, IQR: 0-6, 
placebo +5%, IQR: 0-15) [42]. The survival benefit with 
the use of metformin in breast cancer is being evaluated 
in 3 clinical trials, however there is no data presently 
available (NCT01627067, NCT0131023, NCT01885013).
Metformin is presently being evaluated as an 
anti-cancer agent for endometrial cancer as well. There 
are 6 ongoing trials (10.9% of all ongoing trials using 
metformin as an anti-cancer agent; Tables 1, 2), with 3 
each for monotherapy and combination chemotherapy. 
The drugs that are currently being assessed in combination 
with metformin for treatment of endometrial cancer 
are carboplatin, everolimus, letrozole, paclitaxel, and 
megestrol acetate. One trial is assessing the role of 
metformin as a maintenance therapy. In conjunction with 
clinical response, the effect of metformin on endometrial 
cancer is being studied through a wide variety of 
markers including Ki67, pS6, Akt, pAMPK, ERK1/2, 
histone H3, telomerase, topoisomerase IIα and p27. The 
effect of using metformin on expression of estrogen 
(ER) and progesterone (PR) receptors in cancer tissue 
of endometrial origin is also being investigated. Three 
completed trials, all pre-surgical window of opportunity 
trials using metformin monotherapy, have shown a 
significant decrease in Ki67 staining [43-45] and in pS6 
staining [44, 45]. One trial also reported a reduction in 
Oncotarget40774www.impactjournals.com/oncotarget
table 3: Anti-tumor activity of metformin in metastatic tumors
cancer type Phase Primary outcome/conclusion dosing regimen combination
enrollment 
no. status results
clinical trial 
identifier/ 
reference
Breast Phase I MTD of metformin when used with erlotinib
Initial metformin dose will be 850 mg BID 
and escalated to maximum FDA approved 
dose of 850 mg TID. DLT will be determined 
during the first 5 weeks of therapy; erlotinib 
150 mg daily.
metformin, erlotinib 20 Recruiting NA
NCT01650506
Breast Phase II PFS assessed at 2 months 
Exemestane 25 mg PO QD, everolimus 10 
mg PO daily and metformin 500 mg PO daily 
for 3 days. If DLT does not occur, metformin 
dose will be escalated by 500 mg PO every 
3 days to reach target of 1000 mg PO BID
metformin, 
exemestane 40
Active 
but not 
recruiting
NA
NCT01627067
Breast Phase II RCT
PFS (assessed up to 3 
years)
Metformin 850 mg BID in addition 
to standard chemotherapy consisting 
anthracyclines, platinum, taxanes or 
capecitabine
metformin, standard 
chemotherapy 
(anthracycline, 
platinum, taxanes 
or capecitabine)
78 Recruiting NA
NCT01310231
Breast Phase II RCT
PFS (assessed up to 42 
months)
Cycle 1- ONLY metformin from day 1-13, 
chemotherapy initiated from day 14; day 1-3- 
metformin 1000 mg QD, day 4- metformin 
1000 mg BID; Myocet 60 mg/m2 IV on day 
1, every 21 days; Cyclophosphamide 600 mg/
m2 IV at day 1 every 21 days
metformin, myocet, 
cyclophosphamide 112 Recruiting NA
NCT01885013
Colorectal Phase II Progression assessed at 12 weeks
Irinotecan 350mg/m² q21d + metformin up 
to 2500mg/day
metformin, 
irinotecan 41
Not yet 
recruiting NA
NCT01930864
Colorectal Phase II Disease control rate (assessed every 8 weeks) 
metformin 850mg PO BID plus 5FU 425mg/
m2 plus leucovorin 50mg IV weekly
metformin, 5FU, 
leucovorin 50 Recruiting NA
NCT01941953
Lung Phase II 
RCT
PFS (assessed at 1 
year) of metformin plus 
standard chemotherapy
Metformin started at 500 mg BID PO. Dose 
increased to 1000 mg as 1st dose and 500 
mg as 2nd dose of the day after 1st week. 
After another week, dose will be 1000 mg 
BID. Metformin initiated 1 week before 
chemotherapy. Paclitaxel 200 mg/m² IV, 
day 1 of each cycle. Carboplatin at AUC= 
6 mg/ml IV following paclitaxel, every 21 
days. Bevacizumab 15 mg/kg every 21 
days, after completion of chemotherapy, 
starting with cycle 1. After 4 cycles 
of induction chemotherapy, continue 
bevacizumab at 15 mg/kg every 21 days 
until disease progression.
metformin, 
paclitaxel, 
bevacizumab, 
carboplatin
60 Recruiting NA NCT01578551
Melanoma Phase II RR defined by the ratio 
between total number 
of patients with a 
complete response 
(CR) or partial 
response (PR).
2540 mg/day of metformin-base metformin 
monotherapy
20 Unknown NA NCT01840007
Melanoma Phase II 
RCT
RR Dacarbazine 1000 mg/m2 once every 28 
days with Metformin 850 mg BID
metformin, 
dacarbazine
96 Recruiting NA NCT02190838
Neuro-endocrine Phase II Disease free survival 
(assessed at 180 days)
Metformin 850mg BID metformin 
monotherapy
30 Recruiting NA NCT02279758
Ovarian, 
fallopian tube, 
or primary 
peritoneal cancer
Phase II 
RCT
PFS Chemotherapy options- 1. Paclitaxel IV 
over 2-3 hours + carboplatin IV on day 1; 
2. Docetaxel IV over 1 hour + carboplatin 
IV on day 1; 3. Paclitaxel IV on days 
1, 8, and 15 + carboplatin IV on day 1. 
Patients randomized to 1 of 2 treatment 
arms and will receive metformin PO BID 
with chemotherapy for 6 courses (21 days 
cycle).
metformin, 
paclitaxel, 
carboplatin, 
docetaxel
160 Recruiting NA NCT02122185
Pancreas Phase I To evaluate the 
toxicity, feasibility 
and compliance of 
chemotherapy regimen
Gemcitabine HCl and paclitaxel albumin-
stabilized nanoparticle formulation IV 
on days 1, 8, 15. Patients also receive 
metformin PO BID from day (-)6 and 
dietary supplement PO BID from day (-)3. 
Cycles repeat every 28 days.
metformin, 
gemcitabine, 
paclitaxel
21 Not yet 
recruiting
NA NCT02336087
Pancreas Phase I, 
Phase II 
RCT
To evaluate feasibility 
and safety of metformin 
plus rapamycin versus 
rapamycin alone after 
stabilization of disease 
on chemotherapy.
Arm A- metformin 850mg PO BID on a 28 
day cycle, Arm B- metformin 850mg PO 
BID plus rapamycin 4mg PO QD on a 28 
day cycle.
metformin, 
rapamycin
22 Recruiting NA NCT02048384
Pancreas Phase II Radiological evidence 
of disease control
Paclitaxel 80 mg/m2 IV day 1, 8, 15; 
metformin 850mg PO TID
metformin, 
paclitaxel
41 Completed 6 patients (31.6%) 
showed stable 
disease; Median 
overall survival: 
133 days; Median 
PFS: 43 days. 8 
patients (42.1%) 
had treatment-
related grade 
3-4 toxicities 
with 6 cases 
(31.6%) requiring 
metformin dose 
reduction due 
to diarrhea; 
paclitaxel dose 
decreased in 1 
case because 
of febrile 
neutropenia. 
NCT01971034 
[46]
Pancreas Phase II RR as determined by 
CT/MRI and PFS
Metformin PO BID days 1-14 and 
FOLFOX therapy comprising leucovorin 
calcium IV, fluorouracil IV, and oxaliplatin 
IV on day 1. Cycles repeated every 14 days.
metformin, 
FOLFOX 
(leucovorin 
calcium, 
fluorouracil, 
oxaliplatin)
43 Recruiting NA NCT01666730
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topoisomerase IIα and ERK 1 / 2, along with significant 
elevation in pAMPK and p27 [45]. A different trial 
reported a decrease in tumor cell proliferation by 11.75% 
and a decrease in expression of ER with the use of 
metformin. PR expression, however, was not affected [43]. 
Thus far, no trial has provided any data on survival benefit 
with the use of metformin in endometrial cancer, though 
one trial is ongoing (NCT02065687).
Metformin is being assessed in combination with 
various anti-cancer agents for the treatment of pancreatic 
cancer. Presently, there are 7 ongoing and 2 completed 
trials (Tables 2-4). With the exception of one trial where 
the treatment regimen involves using metformin together 
with stereotactic radiosurgery (Table 4), all others are 
using metformin in combination with different anti-cancer 
agents. These include cisplatin, capecitabine, epirubicin, 
erlotinib, everolimus, gemcitabine, octreotide, paclitaxel, 
rapamycin, and FOLFOX (fluorouracil, oxaliplatin, 
leucovorin). The effects of metformin are being assessed 
mostly through clinical outcomes including progression 
free survival (PFS), recurrence free survival (RFS) and 
toxicity due to chemotherapy combination. The results 
from a phase II non-randomized trial showed that the 
combination of metformin plus paclitaxel was not 
well tolerated, with 42.1% patients experiencing grade 
3-4 toxicities. A total of 31.6% cases had to undergo 
metformin dose reduction secondary to development of 
diarrhea, while one case experienced febrile neutropenia 
which was attributed to paclitaxel. This trial reported a 
median overall survival (OS) of 133 days and median PFS 
as 43 days, but could not meet the disease control rate 
endpoint [46]. Another trial, consisting of 120 participants 
randomized to metformin or placebo arm, noted that 
although the combination of metformin, gemcitabine and 
Pancreas Phase II 
RCT
PFS at 6 months Cisplatin and epirubicin at 30 mg/m2 on 
days 1 and 15, gemcitabine at 800 mg/m2 
on days 1 and 15, capecitabine at 1250 mg/
m2 days 1-28, metformin at 2000 mg/day 
days 1-28
metformin, 
cisplatin, 
epirubicin, 
gemcitabine, 
capecitabine
82 Active 
but not 
recruiting
NA NCT01167738
Pancreas Phase II 
RCT
Survival after 6 months Gemcitabine 1000 mg/m2 IV given weekly 
for 3 weeks, followed by 1 week without 
gemcitabine; erlotinib 100 mg daily; 
metformin 500 mg BID, if tolerated, dose 
will be increased to 1000 mg BID in 2nd 
week.
metformin, 
gemcitabine, 
erlotinib
120 Completed 6 month survival 
rate for metformin 
arm was 55% 
(95% CI: 42-68) 
and for placebo 
arm was 66% 
(95%CI: 54-78, 
p= 0.23); Median 
overall survival 
was 6.8 months 
(95%CI: 5.3-
8.3) and PFS 
was 4.4 months 
(95%CI: 2.0-6.7) 
in metformin arm 
and for placebo 
arm were 7.6 
(95%CI: 6.3-9.0) 
and 5.4 (95%CI: 
4.7-6.1) months 
respectively; 
Metformin well 
tolerated, when 
compared to 
placebo showed 
no significant 
variation recorded 
in grade ≥3 
toxicity. 
NCT01210911 
[47]
Prostate Phase II PFS (assessed at 12 
weeks)
Metformin lifelong follow-up at 1000 mg 
BID daily until progression, unacceptable 
toxicity or refusal of therapy
metformin 
monotherapy
44 Active 
but not 
recruiting
NA NCT01243385
Prostate Phase II PFS (assessed at 12 
weeks)
Addition of metformin 1000 mg PO BID 
to abiraterone in case of PSA progression
metformin, 
abiraterone
25 Recruiting NA NCT01677897
Prostate Phase II 
RCT
PSA response Docetaxel 75 mg/m2, metformin 850 mg 
PO BID daily
metformin, 
docetaxel
100 Recruiting NA NCT01796028
Advanced solid 
tumors
Phase I MTD of metformin 
when used in 
combination with 
temsirolimus
Metformin 500 mg PO QD/BID/TID daily 
on days 1-28 and temsirolimus 15-25 mg 
IV weekly
metformin, 
temsirolimus
11 Completed - 3/3 patients 
in 1st cohort 
had DLTs 
including grade 
4 pneumonitis, 
grade 3 fatigue 
and grade 3 
thrombocytopenia
- 2/8 patients had 
DLT in 2nd cohort: 
grade 4 dyspnea 
and grade 3 
thrombocytopenia
NCT00659568 
[50]
Advanced 
cancers/ 
metastatic 
cancers
Phase I MTD of temsirolimus 
and metformin
Temsirolimus 25 mg IV weekly; metformin 
titrated over 3 weeks at 500 mg PO daily. 
4 weeks of treatment constitute 1 cycle. 
Cycle 1 to be 6 weeks to allow metformin 
titration.
metformin, 
temsirolimus
104 Recruiting NA NCT01529593
Advanced 
cancers/ 
metastatic 
cancers
Phase I MTD of lapatinib with 
sirolimus or metformin
Lapatinib starting dose 500 mg PO daily for 
21 day cycle, metformin starting dose 1000 
mg PO daily.
metformin, 
lapatinib
106 Active 
but not 
recruiting
NA NCT01087983
Abbreviations: RR, recurrence rate; PFS, Progression free survival; PSA, Prostate specific antigen; MTD, Maximum tolerable 
dose; DLT, Dose limiting toxicity; pCR, Pathological complete response; RCT, Randomized control trial; CBR, Clinical 
benefit rate; IHC, Immunohistochemistry; CI, Confidence interval; PO, taken by mouth; QD, once a day; BID, two times a 
day; TID, three times a day
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erlotinib was well tolerated, the 6 month survival rate was 
55% in metformin arm and 66% in placebo arm. Also, no 
significant difference was observed in PFS and median OS 
between metformin users and non-users [47]. 
Five clinical trials (Tables 1-3) are presently working 
to evaluate if metformin may be of value in the treatment 
of prostate cancer. These include two trials that are using 
metformin as monotherapy and three in combination with 
different agents: abiraterone (NCT01677897), docetaxel 
(NCT01796028), and enzalutamide (NCT02339168). Data 
made available from one trial, a single arm window of 
opportunity study, showed a significant reduction in Ki67 
index and 4E-BP-1 staining with no changes in pAMPK. 
Three of 24 patients developed grade 3-4 toxicities, 
indicating that the treatment was overall well tolerated 
[48]. The effect of metformin therapy on PFS for prostate 
cancer is being assessed in two trials (NCT01433913, 
NCT02339168), with one other trial evaluating PSA 
response (NCT01796028). However, presently there is no 
data available on survival benefit.
There is one phase II trial of metformin use in 
non-small cell lung cancer (NSCLC) combined with 
stereotactic body radiotherapy that is currently recruiting 
patients (NCT02285855). 
There are two completed trials (Table 2, 3) on 
multi-histology solid tumors assessing the dose limiting 
toxicity (DLT) of various treatment regimens that 
include metformin. One of the trials used metformin in 
combination with 26 chemotherapy regimens for 17 tumor 
types on a total of 100 participants. The study was divided 
in two stages. In stage one, participants were randomized 
to receive metformin or placebo with chemotherapy. In 
stage two, participants of delayed arm would be crossed 
over to receive metformin with chemotherapy. Results 
showed that 46% of participants documented stable 
disease. In the sub-set of patients having quantifiable 
tumor markers, 28% exhibited favorable changes. 
The participants receiving metformin together with 
chemotherapy showed a lower rate of DLT (6.1% in stage 
one of concurrent arm, including grade 3 anemia, decrease 
in albumin and elevation in ALT) compared to those who 
received just the chemotherapy (7.8% in stage one of 
delayed arm [including grade 3 syncope, dehydration and 
elevation of bilirubin] and 3.8 % in stage two [including 
table 4: Antitumor activity of metformin in combination with radiotherapy  
cancer type Phase Primary outcome/conclusion dosing regimen combination
enrollment 
no. status results
clinical trial 
identifier/ 
reference
Brain Phase I
Number of 
participants that 
had adverse events 
and the number that 
completed the trial 
(assessed at 8 weeks)
Partial brain re-irradiation to a dose of 30-35Gy 
over 2 weeks (10 fractions) combined with low 
carbohydrate diet and/or metformin
metformin, 
partial brain re-
irradiation
18 Not yet recruiting NA NCT02149459
Head and 
neck locally 
advanced 
squamous cell 
carcinoma
Phase I
MTD 
of metformin when 
used with cisplatin 
plus radiation
metformin administered in escalating doses of 
2000mg, 2550 mg and 3000mg PO starting 1 
week prior to the initiation of chemoradiation 
and ending on the last day of chemo or radiation. 
Cisplatin 100mg/m2 on days 1, 22, and 43, 
Radiation 70 Gy in 2 Gy once daily fractions of 
35 fractions.
metformin, 
chemo-radiation 
(with cisplatin)
30 Not yet recruiting NA NCT02325401
Lung Phase II RCT
Comparing response 
to metformin versus 
placebo 
Metformin for 3 weeks prior to SBRT and for 
1 week during SBRT. Metformin dose- 2000 
mg/day PO (500 mg AM, 1000 mg noon, 500 
mg PM). Metformin started at 1000 mg daily in 
divided doses for 1 week. SBRT delivered per 
standard of care.
metformin, SBRT 70 Recruiting NA NCT02285855
Lung Phase II RCT PFS (assessed for up to 12 months)
Metformin 500 mg BID PO for week 1, 1500 
mg/day in week 2 and 2000 mg/day at week 3 
and then for a period of 12 months. Cisplatin-
based chemotherapy with standard radiotherapy 
of 60-63 Gy for 6 weeks.
metformin, 
cisplatin-based 
chemotherapy, 
standard 
radiotherapy
94 Recruiting NA NCT02115464
Lung Phase II RCT PFS (assessed for 
up to 5 years)
Metformin PO BID or TID x14 days. Day 
15 onwards patients receive paclitaxel IV 
and carboplatin IV on days 1, 8, 15, 22, 29, 
36 and undergo radiation therapy (3D-CRT 
or IMRT) QD 5 days/week for 6 weeks and 
receive metformin BID/TID for 6 weeks. 
From 28-42 days after radiotherapy, patients 
receive consolidation chemotherapy with 
paclitaxel IV and carboplatin IV on days 1 and 
22 and metformin PO BID/TID for 10 weeks. 
Consolidation chemotherapy repeated every 3 
weeks for 2 courses.
metformin, 
paclitaxel , 
carboplatin, 
radiotherapy 
(3D-CRT 
or IMRT), 
consolidation 
chemotherapy 
with paclitaxel 
and carboplatin
168 Recruiting NA NCT02186847
Pancreas NA DLT (assessed up 
to 21 days after 
therapy)
Metformin PO or BID on days (-)11 to (-)1. 
Patients then undergo stereotactic radiosurgery 
5 days/week and receive concurrent metformin 
PO BID for 5 weeks. Patients undergo 
laparotomy in week 6 (or weeks 5-7). 
Systemic therapy continues as soon as it is 
considered feasible by treating physicians.
metformin, 
stereotactic 
radiosurgery
20 Not yet recruiting NA NCT02153450
Abbreviations: PFS, Progression free survival; DLT, dose limiting toxicity; MTD, Maximum tolerable dose; RCT, Randomized 
control trial; SBRT, Stereotactic body radiation therapy; 3D-CRT, 3D Conformal radiotherapy; IMRT, Intensity modulated 
radiation therapy; PO, taken by mouth; QD, once a day; BID, two times a day; TID, three times a day
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dehydration, vomiting and proteinuria]). The participants 
reporting DLTs in stage two of delayed arm were known 
cases of adverse events with chemotherapy [49]. The 
other trial used metformin and temsirolimus combination 
in 11 patients. It reported that 100% of participants had 
grade 1 toxicity and 82% experienced grade 2 toxicity, 
with DLT being reported in all 3 patients of the first 
cohort (grade 4 pneumonitis, grade 3 fatigue and grade 
3 thrombocytopenia). In the second cohort, the dose of 
temsirolimus and metformin was reduced and DLT was 
observed in only two of eight cases (grade 4 dyspnea and 
grade 3 thrombocytopenia). After 2 months of treatment, 
5 patients had stable disease, 1 case had partial response 
and 2 showed progression [50].
dIscussIon
There is great excitement surrounding metformin 
as a potential anti-cancer agent. Epidemiological data 
has associated the use of metformin with a decrease in 
the risk of developing cancer and a reduced cancer related 
mortality. The information that has been gathered from 
preclinical studies has provided encouraging evidence 
for anticancer mechanisms of metformin. It has been 
suggested that metformin may well be used as a radiation 
sensitizer or an immunotherapy drug, in addition to a 
direct anti-proliferative agent for the treatment of cancer. 
The anticancer mechanism of metformin has been 
extensively studied and attributed to mTOR inhibition. 
More recent data has revealed an immunomodulatory 
effect on cancer cells. Pre-clinical data has demonstrated 
that metformin can inhibit apoptosis of CD8+ TILs. In 
addition, it also increases the effector memory T cell 
population through phenotype switching of CD8+ TILs, 
thus enhancing the immune response against tumor cells 
[26]. The use of metformin with an experimental cancer 
vaccine (LmOVA) showed an increase in the number 
of CD8+ memory T cells that conferred immunity to 
cancer [27]. The recent breakthrough developments in 
immunotherapy for patients with advanced melanoma, 
triple negative breast cancer, and non-small cell lung 
cancer with check point blockade monoclonal antibodies 
(anti-PD-1/L1) have generated excitement in the oncology 
community [51-53] . Immunomodulatory properties of 
metformin have yet to be studied in combination with other 
forms of immunotherapy, in particular with check point 
blockade monoclonal antibodies. Further investigation 
into a possible synergistic effect is warranted. 
The preliminary results from clinical trials assessing 
metformin as an anti-cancer agent have shown that 
metformin can significantly impact markers of tumor 
proliferation. A total of 19 ongoing and completed trials 
(Table 1) are using various surrogate markers to assess 
pro-apoptotic effects of metformin on cancer cells. 
Although majority of these trials are being performed on 
breast and endometrial cancer cases, a limited number of 
trials are also evaluating tumors of head & neck, prostate, 
bladder, lung, kidney and lymphoma.
Pre-surgical window of opportunity trials in 
endometrial and breast cancer showed that tumor markers 
such as Ki67 and TUNEL (indicative of changes in 
cell proliferation and apoptosis respectively) exhibited 
favorable anti-tumor effect. Two trials demonstrated 
favorable changes in Ki67 and TUNEL in a subset of 
women without insulin resistance as compared to those 
with insulin resistance. Although the findings were not 
statistically significant, the direction of change suggests 
an intriguing hypothesis. The use of metformin in patients 
without insulin resistance may offer more benefit as 
compared to those with insulin resistance. 
Diabetes is known to be associated with insulin 
resistance [54] and an impaired immune response against 
various pathogens [55, 56]. The immune system responds 
to the proliferating tumor cells by increasing production 
of tumor specific lymphocytes which check tumor growth 
by various mechanisms [57]. Evidence from preclinical 
trials has described that metformin, at least in part, exerts 
an anti-cancer effect by inhibiting immune exhaustion 
of CD 8+ TILs [26], thus amplifying the existing 
immune action against cancer cells. Therefore, it may 
be hypothesized that the patients with insulin resistance 
have a compromised immune system, which consequently 
results in a sub-optimal anti-cancer effect of metformin. 
It might be rational to stratify outcomes according to the 
insulin resistance status of participants in future clinical 
trials in order to better appreciate the anti-cancer activity 
of metformin.
Fourteen ongoing trials (Tables 1-4) are presently 
amassing evidence to ascertain if a survival benefit 
is associated with the use of metformin in various 
malignancies. These include tumors of the breast, 
pancreas, lung, endometrial, brain, prostate and 
gynecological cancers. Thus far, there are results available 
from two clinical trials on metastatic pancreatic cancer, 
neither of which had favorable outcomes. From this data, 
it can be speculated that metformin may not be viable 
option for the treatment of advanced pancreatic cancer. 
The upcoming clinical trials may need to shift focus 
towards treating earlier stages of pancreatic cancer or 
using a different combination of agents with metformin 
to have better outcomes in advanced disease. Additional 
data on survival indices from multiple ongoing trials will 
be pivotal to draw a better conclusion. 
One concern with the clinical utility of metformin 
is its side effect profile, particularly in combination with 
cytotoxic chemotherapy. Metformin is well known for 
causing GI upset, sometimes limiting patient compliance 
due to discomfort. Clinical trials have revealed a low 
incidence of DLTs with metformin in combination with 
a wide variety of chemotherapy regimens [48]. With this 
data, clinicians can be reassured that metformin will most 
likely be a tolerable addition to a chemotherapy regimen, 
Oncotarget40778www.impactjournals.com/oncotarget
and should not limit its practical utility. 
conclusIons
A strong base of epidemiological and pre-clinical 
data has prompted attempts to probe the anti-cancer effects 
of metformin through clinical trials. Metformin has been 
shown to have a favorable effect on markers of tumor 
proliferation but it remains to be seen if that translates 
to benefit in survival rates. It is prudent to find better 
histology and the appropriate stage of tumors for utilizing 
metformin therapy. The potential use of metformin as 
an immunotherapy agent needs to be substantiated with 
further evidence to ascertain possible benefits in future.
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